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The first comprehensive analysis of whether acamprosate treatment works as well for alcohol-dependent women as for men definitively
concludes that across 22 mainly European trials it has had a virtually identical impact. The analysis also reports the drug's overall impact,
finding that it helps prevent heavy drinking as well as fostering abstinence.
Summary Traditionally alcohol dependence has been seen as a man's disease, and much of our understanding derives from studies largely of
men. In particular, little is known about the efficacy of medications for alcohol dependence in women, including disulfiram, naltrexone, and
acamprosate.
The featured analysis addresses this gap in respect of acamprosate, an oral prescription medication for the maintenance of abstinence in
individuals with alcohol dependence. Acamprosate normalises neurotransmitter systems disrupted when alcohol-dependent individuals stop
drinking, helping prevent this disruption from prompting relapse. In 23 trials in 18 countries which randomly allocated over 6000 patients to
placebo or acamprosate, the drug has been shown to significantly increase the rate of abstinence relative to placebo without causing serious
adverse effects. It is the most widely prescribed alcohol dependence medication in the United States.
However, only 22% of participants in acamprosate trials have been women, and outcomes have not been reported separately across these
trials for men versus women, leaving it unclear whether the drug is equally effective and safe for both sexes.
The featured analysis searched for high quality trials available up to February 2011 which had randomly allocated patients to placebo or
acamprosate. They had to have hidden this allocation from both patients and research assessors and reported impacts on some measure of
drinking. The search included as yet unpublished trials and a request for trial data from the drug's developers.
Of the 22 such studies of adult patients, 17 had been conducted in Europe including one from the UK. In all, the trials involved 1317 women
patients and 4794 men. Typically the trials excluded patients suffering significant psychiatric or medical disorders or dependent on other
substances except tobacco. In all but three trials patients had to have stopped drinking for at least two days before being allocated to their
medications. As well as medications, generally they received the alcoholism counselling offered at the participating clinics.
Compared to the men, the women in these trials were significantly more likely to be divorced or widowed and to also have suffered from drug
abuse, anxiety, depression, and nonspecific psychiatric problems, and 22% versus 13% had attempted suicide. Despite being alcohol
dependent for fewer years and drinking less, women exhibited significantly worse signs of impaired liver functioning.
Main findings
Outcomes were amalgamated across the trials using techniques. In analysing drinking outcomes, patients who had left trials
early were considered to have been drinking through to the end of the trial unless the reason was clearly unrelated, such as moving out of
the area. In general, relative to placebo the results showed acamprosate to have curbed drinking and heavy drinking about equally and to
have caused no more adverse effects in women versus men.
Specifically, compared to placebo (average 43% days abstinent) acamprosate led to an extra 10% of days of non-drinking. Across placebo and acamprosate
patients, women and men were abstinent on virtually the same proportions of days (48% and 47%), and the extra impact of taking acamprosate was about the
same for both sexes (11% for women and 10% for men). Similarly, the 19% of placebo patients who sustained non-drinking throughout the trials was improved to
28% by acamprosate and improved roughly equally among women (from 17% to 25%) and men (from 19% to 28%).
Days when patients had drunk 'heavily' were defined as consuming at least 56g alcohol (seven UK units) for women and at least 70g (about nine UK units) for men.
Across the trials placebo patients managed not to drink heavily on 53% of days, a figure improved by 11% by acamprosate. The extra impact of taking
acamprosate was about the same among women (increased from 55% to 65%) and men (52% to 62%). Results were similar for the proportions of patients who
avoided heavy drinking altogether, increased among women from 15% on placebo to 24% on acamprosate, and among men from 32% to 43%.
Compared to placebo, across both sexes acamprosate was associated with significantly higher rates of treatment completion (56% v. 52%) and compliance with
taking medication (76% v. 72%). Acamprosate patients were no more likely than placebo patients to experience adverse events (and in particular, gastrointestinal,
the main type associated with acamprosate) or as a result to leave the trials, and this was equally the case for women and men. However, across placebo and
acamprosate patients, women reported significantly more at least moderately severe adverse events than men – 28% v. 20%.
Impacts of acamprosate on drinking outcomes varied substantially across the trials, particularly among male patients.
The authors' conclusions
The analysis shows that, compared to a placebo, acamprosate significantly improves rates of abstinence and no heavy drinking in both
women and men with alcohol dependence, and also leads to significantly more patients completing treatment and taking their medication as
intended. Women and men tolerated the drug equally well. The implication is that treatment providers may routinely consider acamprosate for
treating alcohol dependence in both women and men, taking into account the patient's treatment goals and preferences as well as safety
considerations specific to that individual.
In this, the largest trial-based dataset of women seeking treatment for alcohol dependence to date, despite a history of significantly more
anxiety, depression, suicide attempts, drug abuse, interpersonal loss, and greater liver impairment than men, women responded comparably
well to alcoholism treatment.
The results of this analysis are likely to be applicable to routine clinical practice because generally the clinics' routine counselling was provided and patients entered
treatment in the normal way. However, some categories of patients were excluded. Selection of only rigorous trials suggests the amalgamated results can be relied
on. However, results did vary substantially across the trials. Causes of this variation may include the recruitment of non-dependent patients to one of the trials,
among whom acamprosate would not have been able to exert its normalising impact on neural systems because these would not have been disrupted by
dependence and withdrawal; this trial was the only to have found acamprosate counterproductive among women. Similarly, results of a British trial which found
negative effects of acamprosate among men could have been due to the recruitment of patients who were still drinking when they started treatment, so were yet to
experience the neural disruption which acamprosate helps reverse.
 The distinctive contribution of the featured analysis is to definitively confirm that on the evidence to date, alcohol-dependent
women seeking treatment respond as well to acamprosate as men. In both sexes it typically made a modest but worthwhile contribution to
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sustaining abstinence and avoiding heavy drinking.
The analysis also offers a valuable update on the overall effectiveness of acamprosate across the sexes. With respect to abstinence, the
results accord with a review conducted for the Cochrane Collaboration. This found that across all trials acamprosate reduced the risk of a
return to drinking after detoxification to 86% of the risk with a placebo and increased the average time patients sustained abstinence by
11%. However, results differed in respect of heavy drinking. In the Cochrane analysis, across the six trials which yielded this data
acamprosate made virtually no difference to the proportion of patients who returned to heavy drinking, though across seven trials, a
biochemical marker indicative of heavy drinking was lower on acamprosate than on placebo, a finding which just failed to reach statistical
significance. In contrast, with many more trials (about 20) to draw on, and a uniform and more precise definition of heavy drinking as
excessive consumption on a single day, the featured analysis did find a significant improvement with acamprosate about as large as that
found for the abstinence outcomes.
The Cochrane analysis agreed with the featured analysis that patients on acamprosate were slightly less likely (9% fewer) to drop out of
treatment, but did find they were much more likely (35% more) to drop out early due to side effects and other adverse events, of which
diarrhoea was the only one reported significantly more often on acamprosate. However, the numbers involved were generally few and the
great majority of patients on either acamprosate or placebo completed the early phases of treatment.
The featured analysis attributes acamprosate's poor record in the major British trial to patients not having stopped drinking when they
started the medication. Indeed, of patients did not remain abstinent for the week before being randomised into the study, a
requirement in some other studies. Outcomes in the British study may also have suffered from the drug in the immediate post-
withdrawal period, when theory suggests its effectiveness should be at its height, the reason why UK guidance stipulates that acamprosate
should be started "As soon as possible after assisted withdrawal". Also, many of the patients were episodic heavy drinkers and high drop-out
and non-compliance rates meant that just a third of the sample completed the study, and by the end fewer than 30% were taking at least
90% of their tablets.
In contrast, in the major UK naltrexone trial, patients who completed the study and largely complied with treatment drank substantially less
on naltrexone than on placebo tablets. One lesson from both trials seems to be that among typical British alcohol clinic caseloads, the
support available from the staff and/or from families and friends is often insufficient to enable patients to sustain their commitment to
treatment.
UK policy and practice
On the basis of the evidence, acamprosate, disulfiram and naltrexone are all endorsed in national guidance for Scotland and England and
Wales. The guidance envisages a more routine and/or first-line post-detoxification role for acamprosate than for disulfiram, the latter coming
with the caution that total abstinence is required to avoid unpleasant and potentially dangerous reactions, and that the positive evidence
derives from situations where consumption has been supervised. Naltrexone is seen as fulfilling a similar role to acamprosate, but at the time
the guidance was drafted it had no UK licence for the treatment of alcohol dependence, so the Scottish advisers felt they could not
commend it for use in the NHS.
Statistics for England in 2012 show that doctors in general have forefronted acamprosate, prescribed 117,405 times compared to 60,842 for
disulfiram, figures dominated by GP prescribing. However, in hospitals disulfiram is prescribed slightly more often. In these settings patients
are likely to be so severely dependent that at least initial abstinence is the preferred objective, and there is the support for patients and the
expertise to handle the risks of prescribing disulfiram.
For more on alcohol treatment medications see these Findings analyses of an omnibus review, and of reviews focused on acamprosate and the main alternative,
naltrexone. Another review has focused on disulfiram, a different type of medication which aims not to help patients cut back but to enforce abstinence due to the
aversive effects of drinking while the drugs is active in the body.
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